HOME >> BIOLOGY >> NEWS
MRI studies provide new insight into how emotions interfere with staying focused

DURHAM, N.C. -- Duke University researchers have shown how emotions such as fear or horror travel along separate paths through the brain and are more likely than simple distractions to interfere with a person's efforts to focus on a task such as driving.

Using functional MRI to watch human brains in action, the researchers showed that emotional stimuli and "attentional functions" like driving move in parallel streams through the brain before finally meeting up in a specific part of the brain's prefrontal cortex.

The results, published in the August 20 issue of The Proceedings of the National Academy of Sciences (PNAS), help explain why a person who suddenly feels a pang of emotion is especially likely to lose focus. They also may lead to new avenues of research for treating depression, attention-deficit disorder, post-traumatic stress syndrome and other disorders.

"We've known for a long time that some people are more easily distracted and that emotions can play a big part in this," said Kevin S. LaBar, assistant professor at Duke's Center for Cognitive Neuroscience and an author of the study. "Our study shows that two streams of processing take place in the brain, with attentional tasks and emotions moving in parallel before finally coming together." The two streams are integrated in a region of the brain called the anterior cingulate, which is located between the right and left halves of the brain's frontal portion and is involved in a wide range of thought processes and emotional responses.

LaBar and his colleagues used functional MRI devices to study the brains of neurologically healthy subjects who tried to pay attention to specific visual targets on a screen. The test subjects were distracted in various ways, sometimes by images that were likely to evoke an emotional response. The results confirmed previous findings that emotional stimuli are more likely to cause a person to lose focus. However, they also shed light on the
'"/>

Contact: David Jarmul
david.jarmul@duke.edu
919-684-6815
Duke University
19-Aug-2002


Page: 1 2

Related biology news :

1. Rensselaer marks the opening of the center for biotechnology and interdisciplinary studies
2. UCSD undergraduates participate in collaborative studies abroad on cyberinfrastructure
3. Scientist honored for studies of genetic influence on chemotherapy, tumor development
4. $5 million grant funds partnership, studies of minority-based issues in reproductive health
5. Synthetic hormone used in contraceptives and HRT produces negative effects in monkey studies
6. $5.5 million awarded to tree-ring research and climate studies
7. Pancreatic cancer blood test & gene studies show promise
8. Two studies weigh in on low-carb diets
9. Animal studies show promise treating severe chronic pain
10. New studies show Curves Program raises metabolic rate in overweight and sedentary women
11. Florida Tech researchers win $912,700 grant for cell studies

Post Your Comments:
(Date:10/29/2014)... who lose their hair as a consequence of chemotherapy ... improve the scalp cooling technology that prevents hair loss. ... being pioneered by global scalp cooling manufacturing company, Paxman ... biology department of the University of Huddersfield. , The ... who has a background in the pharmacology of cancer ...
(Date:10/29/2014)... research presented at the Society for Integrative Oncology ... for the first time that it is possible ... readily available nutritional supplement, AHCC. ... Smith, Pharm.D., associate professor in the Department of ... of Texas Health Science Center at Houston (UTHealth) ...
(Date:10/29/2014)... Many factors, both genetic and environmental, have been ... of schizophrenia. Some, such as a family history ... infection with Toxoplasma gondii , a parasite ... are still viewed with skepticism. , A new ... and epidemiology at the University of Pennsylvania,s School ...
Breaking Biology News(10 mins):New technology on the way to aid cancer suffers who lose their hair after chemotherapy 2HPV infections in women eradicated by AHCC, Japanese mushroom extract 2Penn vet professor investigates parasite-schizophrenia connection 2Penn vet professor investigates parasite-schizophrenia connection 3
(Date:10/27/2014)... and TORONTO , Oct. ... www.generex.com ) (OTCQB: GNBT) today announced two presentations ... triggered by its novel proprietary cancer immunotherapeutic AE37 ... breast cancer patients. The AE37 cancer vaccine is ... Express, Inc. ( www.antigenexpress.com ). The presentations are ...
(Date:10/27/2014)... Orlando, Florida (PRWEB) October 27, 2014 ... aims at reducing and eliminating several types of ... have not been achieved in over 30 years ... of Noah's Light Foundation, proves that one mom's ... was diagnosed just before Halloween trick-or-treating, and it’s ...
(Date:10/27/2014)... October 27, 2014 Investor-Edge has ... (NASDAQ: NBIX ), Insmed Inc. (NASDAQ: ... BCRX ), Dyax Corporation (NASDAQ: DYAX ), ... five companies can be accessed at: http://investor-edge.com/register ... Composite ended at 4,483.72, up 0.69%, the Dow Jones ...
(Date:10/25/2014)... 2014 ViaDerma, Inc ... devoted to bringing new products to market, is ... ViaDerma has developed an innovative, patent-pending dual carrier ... transfer of pharmaceutical active ingredients to penetrate the ... localized therapy. The transdermal delivery method also overcomes ...
Breaking Biology Technology:Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 2Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 3Generex Announces Presentations Correlating Immunological Response with Reduced Recurrence in Phase II Study of AE37 Breast Cancer Vaccine in Patients at the American College of Surgeons 4FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 2FDA Approves Breakthrough in Pediatric Brain Cancer - First in 30 Years 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 2Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 3Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 4Pre-market Equity Watch on Biotech Industry - Neurocrine Biosciences, Insmed, BioCryst Pharma, Dyax, and Oncothyreon 5ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 2ViaDerma, Inc. Announces Plans to Pursue Out-Licensing Partnerships in 2015 3
Cached News: